



### Proteins & Antibodies Program:

#### Day 1 Track 1: Antibody Discovery & Engineering

- Novel engineering strategies to enhance antibody functions
- Advanced technologies for new antibody discovery
- Rational protein design via structure-based tools
- Computational advances in protein engineering
- AI-driven antibody design & optimization

#### Day 1 Track 2: Next-Gen Biologic Targets & Fusion-Based Therapeutics Approaches

- Multi specific immune cell engagers
- Next generation multi-specifics
- Identifying & validating new, difficult targets
- Targeting complex membrane proteins
- Tissue targeting & conditional activation of biologic
- Targeting different cell populations
- New modalities > modulating the tumour microenvironment

#### Day 2 Track 1: Tools & Technologies For Antibody Discovery & Selection

- Addressing difficult targets with display technologies
- Developing novel in vitro display technologies for antibody discovery & engineering
- Antibody selection for poly-specificity & developability
- Generating antibody libraries: NGS, cloning B cells, synthetic libraries

#### Day 2 Track 2: Computational Tools & AI/ML-Guided Engineering

- Innovative de novo antibody generation
- Structural approaches to protein engineering
- Computational and analytical tools for protein engineering
- High-throughput & low-throughput methods: application of
- AI/ML & deep learning tools in antibody engineering
- Computational epitope mapping
- AI-driven structural prediction
- Use cases & prediction tools

### ADC Discovery & Development Program:

#### Day 1 Track 3: Engineering Conjugates

- Strategies to optimise the design of ADCs
- Linker/payload technologies to achieve better therapeutic index
- Tailoring ADC design to specific targets
- Validating novel ADC targets, including next generation conjugates
- Translational biomarkers to support research from discovery to the clinic
- Antibody fragments for ADC optimisation

#### Day 1 Track 4: ADC CMC, Manufacturing & Process Development

- Streamlining antibody drug product development
- CMC strategies for effective ADC development
- Shortened ADC manufacturing timelines
- Analytical development


#### Day 2 Track 3: Translating ADCs to the Clinic

- Maximising the efficacy of ADCs
- Developing appropriate preclinical models
- Utilising ADCs beyond oncology indications
- Enabling progression through effective biomarkers
- CMC approaches

### Benefits to Attending

- ✓ **Hear from and meet with the 300+ key innovators in drug discovery.** 2024 attendees included: Chief Scientific Officer, LAVA Therapeutics; Associate Vice President, Eli Lilly; Senior Director, Pfizer
- ✓ **Devised with the help of our esteemed advisory board,** our revamped programme is designed to provide in-depth discussion of the key technologies, modalities & platforms transforming large molecule drug discovery
- ✓ **New to 2025! Co-located with Discovery US & Formulation & Delivery US,** to attract 1000+ senior attendees across small and large molecule discovery & development
- ✓ **Uncover the next generation of biologics research** and gain the insights you need to overcome the challenges of identifying and validating novel targets, including multi-specifics, cell engagers, ADCs and peptides
- ✓ **With new tools & platforms always under development,** our exhibition hall highlights the most promising products to help you meet your research goals and progress your targets towards the clinic
- ✓ **New to 2025! Do not miss out on attending vibrant presentations on Day 2 as part of the new 'Innovation & Collaboration' programme.** Presentations will look at ADC funding, IP and investment challenges & opportunities

### 2024 Speakers Included:



Amita-Datta  
Mannan,  
Eli Lilly



Matt Chu,  
Astellas



Oliver Kitten,  
Afflogic

### Meet Senior Decision Makers

300+ senior attendees from leading pharmaceutical, biotech, academics, and solution provider companies will be attending. Meet Senior VPs, Directors, & Heads with the following job titles:

Antibody Engineering  
Protein Engineering  
ADCs

Computational Biology  
Antibody Discovery  
Protein Design

### Discover New Solutions

Formal and informal meeting opportunities offer delegates the chance to discuss key solutions with leading service providers. Services to be discussed include:

Bioconjugation  
Antibody Generation  
Characterization Tools

Bispecific Antibody Design  
Conjugation Technology  
Expression Platforms

### 2024 Speakers Included:

- Olivier Kitten, Founder and Chief Executive Officer, Affilogic
- Hans Van der Vliet, Chief Scientific Officer, LAVA Therapeutics
- Rajika Perera, Co-founder and Chief Executive Officer, Poseidon LLC
- Mike Schopperle, Chief Executive Officer, CureMeta
- Jan Schnitzer, Chief Executive Officer & President, PRISM
- Daniel Pereira, Chief Scientific Officer, CrossBridge Bio
- Robert Lutz, Chief Scientific Officer, Iksuda Therapeutics
- Nazneen Dewji, President and Chief Executive Officer, Cenna Biosciences
- Christopher Hart, Chief Executive Officer, Creyon Bio
- Alan Wahl, Chief Executive Officer, Abacus Biosciences
- Linda Horner, Chief Administrative Patent Judge, Patent Trial and Appeal Board, USPTO
- Ramana Doppalapudi, Vice President – Chemistry, Avidity Biosciences
- Amita Datta-Mannan, Associate Vice President & Clinical Team Leader, Eli Lilly
- Aming Zhang, Senior Director, Head of Analytical Development & QC, Pyxis Oncology
- Andrew Vendel, Senior Director, Immunology, Eli Lilly
- Melissa Schutten, Senior Director, Pfizer
- Li Feng, Partner & IP Attorney, Finnegan Henderson Farabow Garrett & Dunner
- Jack Ostrowski, Director – Protein Sciences, Biology, Avidity Biosciences
- Natalie Grinshtein, Director – ADC Discovery, Pfizer
- Yuan Cheng, Director of Hybrid Modality, Amgen
- Michael Cochran, Director – Chemistry, Avidity Biosciences
- Udaya Rangaswamy, Director, Translational Biology, Rondo Therapeutics
- Matt Chu, Director Research, Protein Engineering, Astellas
- Avinash Muppidi, Director, Peptide Therapeutics, Eli Lilly
- Purbasa Patnaik, Associate Director, Drug Product Manufacturing & CMC Biotherapeutics, Exelixis
- Brittney Mills, Associate Director – Biologics CMC Drug Product Development, AbbVie
- Brandon Coyle, Associate Director/Senior Research Scientist II, Gilead Sciences
- Michael McPherson, Research Fellow, AbbVie
- Jean Ge, Patent Attorney, Wolf Greenfield
- Sylvia Yip, IP Counsel, Zentalis Pharmaceuticals
- Brian Hall, Head of US Biologics Characterization, Expression, and Purification, Sanofi
- Suk Hyung, Senior Principal Scientist, Genentech
- Yang Su, Principal Scientist, Bristol Myers Squibb

### *New to 2025!* Featuring Our Vibrant Start Up Zone

The Start Up Zone programme is designed to support young start-ups working on new technologies, platforms, solutions to showcase their innovative thinking and bring new ideas. Featuring on Day 1 of the event, participating companies receive full conference pass, 10-minute pitch and a 1x1m space in the start up zone, alongside their logo being featured on the website and event platform.

To apply, visit the website or email Faye Moffat at [f.moffatt@oxfordglobal.com](mailto:f.moffatt@oxfordglobal.com)

In particular, we welcome start-ups working in the following areas:

#### Topics Will Cover:

- Antibody Discovery
- AI-Guided Protein & Antibody Engineering
- NextGen Therapeutics Platforms
- ADC Discovery

### *New to 2025!* Introducing the 'Innovation & Collaboration' Programme

Running on Day 2 of the event, this programme features 10-minute presentations from emerging biotechs and academic spin-offs advancing biologics and ADC discovery & development, with specific focus on IP, patenting, and funding priorities & challenges. Designed to boost visibility, attract collaborators & partners, it connects innovators with pharma leaders, investors, solution providers, and large biotechs. Don't miss these presentations for cutting-edge ideas and collaboration & partnership opportunities.

#### Topics Will Cover:

- ADCs: Using IP and R&D Trends to Inform Innovation
- Patent Strategies for ADCs
- ADC Therapeutics Funding

**Biologics US 2025 Sponsors:**

**Gold Sponsors:**



**Silver Sponsors:**









**Bronze Sponsors:**





**Networking & Programme Sponsors:**




**Biologics US 2025**  
Day 1 – 2<sup>nd</sup> October 2025

|               |   |   |   |   |  |
|---------------|---|---|---|---|--|
| 08.00 – 08.50 | Registration, Exhibition Opens, Welcome Breakfast   |   |   |   |  |
| 08.50 – 09.00 | Oxford Global's Welcome Address   |   |   |   |  |
| 09.00 – 10.00 | Opening Keynote Address & Fireside Chat:<br>AI-Driven Biologics Discovery & Development                                   |   |   |   |  |
| 10.00 – 11.20 | Morning Coffee & Refreshments, Poster Presentation Sessions, 1-2-1 Meetings x4  |   |   |   |  |
|               | Proteins & Antibodies Program   |   | ADC Discovery & Development Program   |   | Start Up Zone Program  |
|               | Protein & Antibody Discovery & Engineering  | Next-Gen Biologic Targets & Fusion-Based Therapeutics Approaches  | Engineering Conjugates  | ADC CMC, Manufacturing & Process Development  |  |
| 11.20 – 11.45 | Solution Provider Presentation<br><br>   | Platinum Solution Provider Presentation<br><br><i>For sponsorship opportunities please contact <a href="mailto:sponsorship@oxfordglobal.com">sponsorship@oxfordglobal.com</a></i> | Platinum Solution Provider Presentation<br><br><i>For sponsorship opportunities please contact <a href="mailto:sponsorship@oxfordglobal.com">sponsorship@oxfordglobal.com</a></i> | Platinum Solution Provider Presentation<br><br><i>For sponsorship opportunities please contact <a href="mailto:sponsorship@oxfordglobal.com">sponsorship@oxfordglobal.com</a></i> | Attendees are welcome to attend the co-located presentations |
| 11.45 – 12.10 | Industry Presentation:<br>Novel Engineering Strategies To Enhance Antibody Functions                                      | Industry Presentation:<br>Optimizing Biologic Targets For New Disease Areas   | Industry Presentation:<br>Unlocking The Next Horizons In ADC Research   | Industry Presentation:<br>Technical Challenges & Opportunities In Early-Stage ADC Development & Manufacturing   | Start Up Pitches x2  |
| 12.10 – 12.35 | Industry Presentation:<br>Advanced Technologies For New Antibody Discovery  | Industry Presentation:<br>Bispecific T-Cell Engagers  | Industry Presentation:<br>Validating Novel Targets To Maximize The Efficacy Of ADCs   | Industry Presentation:<br>Risk Management In ADC Manufacturing  | Start Up Pitches x2  |
| 12.35 – 13.00 | Solution Provider Presentation<br><br>  | Gold Solution Provider Presentation<br><br><i>For sponsorship opportunities please contact <a href="mailto:sponsorship@oxfordglobal.com">sponsorship@oxfordglobal.com</a></i>     | Solution Provider Presentation<br><br>  | Gold Solution Provider Presentation<br><br><i>For sponsorship opportunities please contact <a href="mailto:sponsorship@oxfordglobal.com">sponsorship@oxfordglobal.com</a></i>     | Attendees are welcome to attend the co-located presentations |
| 13.00 – 14.00 | Lunch, Poster Presentation Sessions, 1-2-1 Meetings x3  |   |   |   |  |
| 14.00 – 14.25 | Solution Provider Presentation<br><br> | Solution Provider Presentation<br><br>   | Solution Provider Presentation<br><br>   | Gold Solution Provider Presentation<br><br><i>For sponsorship opportunities please contact <a href="mailto:sponsorship@oxfordglobal.com">sponsorship@oxfordglobal.com</a></i>     | Attendees are welcome to attend the co-located presentations |
| 14.25 – 14.50 | Industry Presentation:<br>Towards Biologics By Design   | Industry Presentation:<br>CAR-Engineered Cell Engagement  | Industry Presentation:<br>Overcoming Toxicity Challenges  | Industry Presentation:<br>Manufacturing Bioconjugates   | Start Up Pitches x2  |

**Biologics US 2025**  
**Day 1 – 2<sup>nd</sup> October 2025**

|               | Proteins & Antibodies Program  |  | ADC Discovery & Development Program  |   | Start Up Zone Program  |
|---------------|--|--|--|---|--|
|               | Protein & Antibody Discovery & Engineering   | Next-Gen Biologic Targets & Fusion-Based Therapeutics Approaches   | Engineering Conjugates   | ADC CMC, Manufacturing & Process Development  |  |
| 14.50 – 15.15 | <b>Solution Provider Presentation</b><br><br><br>GeneFrontier   | <b>Silver Solution Provider Presentation</b><br><br><i>For sponsorship opportunities please contact <a href="mailto:sponsorship@oxfordglobal.com">sponsorship@oxfordglobal.com</a></i> | <b>Silver Solution Provider Presentation</b><br><br><i>For sponsorship opportunities please contact <a href="mailto:sponsorship@oxfordglobal.com">sponsorship@oxfordglobal.com</a></i> | <b>Silver Solution Provider Presentation</b><br><br><i>For sponsorship opportunities please contact <a href="mailto:sponsorship@oxfordglobal.com">sponsorship@oxfordglobal.com</a></i>  | Attendees are welcome to attend the co-located presentations |
| 15.15 – 16.15 | <b>Afternoon Break &amp; Refreshments, Poster Presentation Sessions, 1-2-1 Meetings x3</b>   |  |  |   |  |
| 16.15 – 16.40 | <b>Solution Provider Presentation</b><br><br>   | <b>Bronze Solution Provider Presentation</b><br><br><i>For sponsorship opportunities please contact <a href="mailto:sponsorship@oxfordglobal.com">sponsorship@oxfordglobal.com</a></i> | <b>Bronze Solution Provider Presentation</b><br><br><i>For sponsorship opportunities please contact <a href="mailto:sponsorship@oxfordglobal.com">sponsorship@oxfordglobal.com</a></i> | <b>Bronze Solution Provider Presentation</b><br><br><i>For sponsorship opportunities please contact <a href="mailto:sponsorship@oxfordglobal.com">sponsorship@oxfordglobal.com</a></i>  | Attendees are welcome to attend the co-located presentations |
| 16.40 – 17.05 | <b>Panel Discussion: Novel Technologies In Antibody Discovery &amp; Engineering</b>  | <b>Panel Discussion: Identifying &amp; Validating New, Difficult Targets</b>   | <b>Industry Presentation: Linker/Payload Technologies For Better Therapeutic Index</b>   | <b>Panel Discussion: Assessing Bottlenecks &amp; Opportunities to Streamline ADC Manufacturing Across Multiple Outsourced Partners</b><br><ul style="list-style-type: none"> <li>Breaking down the challenges of navigating ADC development and manufacturing across multiple outsourcing partners</li> <li>Debating top performing strategies to ensure smooth and timely ADC development across multiple manufacturing partners</li> <li>Setting expectations with manufacturing partners: what works well and what can be improved?</li> </ul> | <b>Start Up Pitches x2</b>                                   |
| 17.05 – 17.30 | <b>Industry Presentation: Best Practice Engineering Approaches</b>   |  | <b>Panel Discussion: ADC Target Selection</b>  |   | <b>Start Up Pitches x2</b>                                   |
| 17.30 – 17.55 | <b>Industry Presentation: AI-Driven Antibody Design &amp; Optimization</b>   | <b>Industry Presentation: Targeting Different Cell Populations</b>   | <b>Industry Presentation: Antibody Fragments For ADC Optimization</b>  | <b>Industry Presentation: Streamlining Antibody Drug Product Development</b>  | <b>Start Up Pitches x2</b>                                   |
| 17.55 – 18.20 | <b>Roundtable Discussion 1: What Are The Benefits &amp; Limitations Of ADC Combinations?</b><br><br><b>Roundtable Discussion 2: The Role Of AI/Machine Learning In Biologics Drug Discovery</b><br><br><b>Roundtable Discussion 3: Antibody Discovery Against Complex Membrane Protein Targets</b> |  |  |   |  |
| 18.20         | <b>Networking Drinks &amp; End of Day 1</b>  |  |  |   |  |

**Biologics US 2025**  
**Day 2 – 3<sup>rd</sup> October 2025**

|               |   |   |   |   |
|---------------|---|---|---|---|
| 07.30         | <b>Registration, Exhibition Opens, Welcome Breakfast</b>  |   |   |   |
| 08.20 – 08.30 | <b>Oxford Global's Welcome Address</b>  |   |   |   |
| 09.00 – 09.25 | <b>Opening Keynote Address:<br/>The Impact Of US Healthcare Policy On Drug Development</b>  |   |   |   |
| 09.25 – 09.30 | <i>Buffer Time – Please make your way to the breakout rooms</i>   |   |   |   |
|               | <b>Proteins &amp; Antibodies Program</b>  |   | <b>ADC Discovery &amp; Development Program</b>  |   |
|               | <b>Tools &amp; Technologies For Antibody<br/>Discovery &amp; Selection</b>  | <b>Computational Tools &amp; AI/ML-Guided<br/>Engineering</b>   | <b>Translating ADCs To The Clinic</b>   | <b>Innovation &amp; Collaboration Programme</b>   |
| 09.30 – 09.55 | <b>Solution Provider Presentation</b><br><br>  | <b>Gold Solution Provider Presentation</b><br><br><i>For sponsorship opportunities please contact<br/> <a href="mailto:sponsorship@oxfordglobal.com">sponsorship@oxfordglobal.com</a></i>   | <b>Gold Solution Provider Presentation</b><br><br><i>For sponsorship opportunities please contact<br/> <a href="mailto:sponsorship@oxfordglobal.com">sponsorship@oxfordglobal.com</a></i>   | <b>Gold Solution Provider Presentation</b><br><br><i>For sponsorship opportunities please contact<br/> <a href="mailto:sponsorship@oxfordglobal.com">sponsorship@oxfordglobal.com</a></i>   |
| 09.55 – 10.20 | <b>Industry Presentation:<br/>Targeting Ion Channels With Antibodies</b>  | <b>Industry Presentation:<br/>AI-Guided Antibody Design</b>   | <b>Industry Presentation:<br/>Overcoming Hurdles: Development<br/>Challenges Of ADCs</b>  | <b>Presentations x2</b>   |
| 10.20 – 10.45 | <b>Silver Solution Provider Presentation</b><br><br><i>For sponsorship opportunities please contact<br/> <a href="mailto:sponsorship@oxfordglobal.com">sponsorship@oxfordglobal.com</a></i> | <b>Silver Solution Provider Presentation</b><br><br><i>For sponsorship opportunities please contact<br/> <a href="mailto:sponsorship@oxfordglobal.com">sponsorship@oxfordglobal.com</a></i> | <b>Silver Solution Provider Presentation</b><br><br><i>For sponsorship opportunities please contact<br/> <a href="mailto:sponsorship@oxfordglobal.com">sponsorship@oxfordglobal.com</a></i> | <b>Silver Solution Provider Presentation</b><br><br><i>For sponsorship opportunities please contact<br/> <a href="mailto:sponsorship@oxfordglobal.com">sponsorship@oxfordglobal.com</a></i> |
| 10.45 – 11.45 | <b>Morning Coffee &amp; Refreshments, Poster Presentation Sessions, 1-2-1 Meetings x3</b>   |   |   |   |
| 11.45 – 12.10 | <b>Bronze Solution Provider Presentation</b><br><br><i>For sponsorship opportunities please contact<br/> <a href="mailto:sponsorship@oxfordglobal.com">sponsorship@oxfordglobal.com</a></i> | <b>Bronze Solution Provider Presentation</b><br><br><i>For sponsorship opportunities please contact<br/> <a href="mailto:sponsorship@oxfordglobal.com">sponsorship@oxfordglobal.com</a></i> | <b>Bronze Solution Provider Presentation</b><br><br><i>For sponsorship opportunities please contact<br/> <a href="mailto:sponsorship@oxfordglobal.com">sponsorship@oxfordglobal.com</a></i> | <b>Bronze Solution Provider Presentation</b><br><br><i>For sponsorship opportunities please contact<br/> <a href="mailto:sponsorship@oxfordglobal.com">sponsorship@oxfordglobal.com</a></i> |
| 12.10 – 12.35 | <b>Industry Presentation:<br/>Cryo-Electron Microscopy For Rational<br/>Drug Discovery</b>  | <b>Panel Discussion:<br/>New Computational Tools To Predict<br/>mAB Affinity</b>  | <b>Industry Presentation:<br/>Preclinical Safety Assessment Of ADCs</b>   | <b>Q&amp;A With Speakers</b>  |
| 12.35 – 13.00 | <b>Bronze Solution Provider Presentation</b><br><br><i>For sponsorship opportunities please contact<br/> <a href="mailto:sponsorship@oxfordglobal.com">sponsorship@oxfordglobal.com</a></i> | <b>Bronze Solution Provider Presentation</b><br><br><i>For sponsorship opportunities please contact<br/> <a href="mailto:sponsorship@oxfordglobal.com">sponsorship@oxfordglobal.com</a></i> | <b>Bronze Solution Provider Presentation</b><br><br><i>For sponsorship opportunities please contact<br/> <a href="mailto:sponsorship@oxfordglobal.com">sponsorship@oxfordglobal.com</a></i> | <b>Bronze Solution Provider Presentation</b><br><br><i>For sponsorship opportunities please contact<br/> <a href="mailto:sponsorship@oxfordglobal.com">sponsorship@oxfordglobal.com</a></i> |
| 13.00 – 14.00 | <b>Lunch, Poster Presentation Sessions, 1-2-1 Meetings x3</b>   |   |   |   |

**Biologics US 2025**  
**Day 2 – 3<sup>rd</sup> October 2025**

|               | Tools & Technologies For Antibody Discovery & Selection                               | Computational Tools & AI/ML-Guided Engineering                                       | Translating ADCs To The Clinic   | Innovation & Collaboration Programme  |
|---------------|---|--|--|---|
| 14.00 – 14.25 | <b>Industry Presentation:</b><br>How Do Complex Antibody Formats Affect PK Properties | <b>Panel Discussion:</b><br>AI-Driven Antibody Design & Optimization                 | <b>Panel Discussion:</b><br>Best Practices For ADC-Combination Research                          | <b>Panel Discussion:</b><br><b>IP Strategies For Antibody-Drug Conjugates</b> <ul style="list-style-type: none"> <li>Monitoring IP success</li> <li>Cross-disciplinary approach in safeguarding IP and investments in ADC R&amp;D</li> <li>Technical expertise</li> </ul> |
| 14.25 – 14.50 | <b>Panel Discussion:</b><br>Advances In Display Technologies                          |  |  |   |
| 14.50 – 15.15 | <ul style="list-style-type: none"> <li>Yeast</li> <li>Mammalian</li> </ul>            | <b>Industry Presentation:</b><br>Data Analysis                                       | <b>Industry Presentation:</b><br>Regulatory Approvals  | <b>Presentations x2</b>   |
| 15.15 – 15.40 | <b>Industry Presentation:</b><br>Yeast Display Technologies                           | <b>Industry Presentation:</b><br>Using Generative AI For Biologics Drug Optimization | <b>Industry Presentation:</b><br>Case Study Of ADCs In Solid Tumors                              | <b>Presentations x2</b>   |
| 15.40 – 16.05 | <b>Industry Presentation:</b><br>New Formats For Reagent Antibodies                   | <b>Industry Presentation:</b><br>Computational Advancements In Protein Engineering   | <b>Industry Presentation:</b><br>Characterizing ADC Safety & Activity In Preclinical Development | <b>Q&amp;A With Speakers</b>  |
| 16.05         | <b>End of Conference</b>  |  |  |   |